Stephen V Liu: Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers
Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on LinkedIn:
Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers now online in the New England Journal of Medicine.
Overall RR 30% with DOR 11.1m, PFS 6.8m, and a very favorable safety profile. NRG1+ lung cancers do not respond well to standard chemotherapy or immunotherapy. The fusions can be hard to find – RNA sequencing is the best way to identify them. Zenocutuzumab is now FDA approved for NRG1 positive lung cancer and pancreatic cancer.
Glad to finally have an approved option for this subset of cancers.
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Authors: Alison M. Schram, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023